• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

染色质修饰蛋白 4C (CHMP4C) 作为一种潜在的乳腺癌治疗靶点,影响乳腺癌细胞的生长和多柔比星耐药性。

Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target.

机构信息

Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou, Zhejiang, 318000, China.

Department of Anesthesiology, Taizhou Municipal Hospital, Taizhou, Zhejiang, 318000, China.

出版信息

J Antibiot (Tokyo). 2024 Feb;77(2):93-101. doi: 10.1038/s41429-023-00683-2. Epub 2023 Nov 22.

DOI:10.1038/s41429-023-00683-2
PMID:37993600
Abstract

Breast cancer (BCa) is one of the common malignancies among women. Doxorubicin (Dox), a type of anthracycline anti-tumor drug, is a first-line chemotherapy drug for BCa. It is badly needed to effectively reverse BCa resistance to Dox and improve the clinical symptoms of BCa. Chromatin Modification protein 4C (CHMP4C) is a subunit of the endosomal sorting complex and is expressed in the nucleus and cytoplasm. CHMP4C has been shown to be overexpressed in multiple types of cancers. However, its possible effects on the progression and drug resistance of BCa are still unclear. In this study, we found CHMP4C was highly expressed in BCa tissues and promoted cell proliferation. In addition, CHMP4C promoted resistance of BCa cells to Dox through targeting Snail. We further found that knockdown of CHMP4C inhibited tumor growth and enhanced sensitivity to Dox in vivo. We therefore thought CHMP4C could serve as a target for decreasing BCa drug resistance.

摘要

乳腺癌(BCa)是女性常见的恶性肿瘤之一。多柔比星(Dox)是一种蒽环类抗肿瘤药物,是 BCa 的一线化疗药物。有效逆转 BCa 对 Dox 的耐药性并改善 BCa 的临床症状,这是非常需要的。染色质修饰蛋白 4C(CHMP4C)是内体分选复合物的亚基,在细胞核和细胞质中表达。已经表明 CHMP4C 在多种类型的癌症中过表达。然而,其对 BCa 进展和耐药性的可能影响尚不清楚。在这项研究中,我们发现 CHMP4C 在 BCa 组织中高度表达,并促进细胞增殖。此外,CHMP4C 通过靶向 Snail 促进 BCa 细胞对 Dox 的耐药性。我们进一步发现,敲低 CHMP4C 抑制体内肿瘤生长并增强对 Dox 的敏感性。因此,我们认为 CHMP4C 可以作为降低 BCa 耐药性的靶点。

相似文献

1
Chromatin-modifying protein 4C (CHMP4C) affects breast cancer cell growth and doxorubicin resistance as a potential breast cancer therapeutic target.染色质修饰蛋白 4C (CHMP4C) 作为一种潜在的乳腺癌治疗靶点,影响乳腺癌细胞的生长和多柔比星耐药性。
J Antibiot (Tokyo). 2024 Feb;77(2):93-101. doi: 10.1038/s41429-023-00683-2. Epub 2023 Nov 22.
2
Knockdown of circ_0006528 Suppresses Cell Proliferation, Migration, Invasion, and Adriamycin Chemoresistance via Regulating the miR-1236-3p/CHD4 Axis in Breast Cancer.circ_0006528 通过调控 miR-1236-3p/CHD4 轴抑制乳腺癌细胞增殖、迁移、侵袭和阿霉素化疗耐药性。
J Surg Res. 2021 Apr;260:104-115. doi: 10.1016/j.jss.2020.10.031. Epub 2020 Dec 14.
3
Chromatin modified protein 4C (CHMP4C) facilitates the malignant development of cervical cancer cells.染色质修饰蛋白 4C(CHMP4C)促进宫颈癌细胞的恶性发展。
FEBS Open Bio. 2020 Jul;10(7):1295-1303. doi: 10.1002/2211-5463.12880. Epub 2020 May 30.
4
Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.在乳腺癌细胞中强制表达hsa-miR-125a-3p可通过调节BRCA1信号增强多西他赛敏感性。
Biochem Biophys Res Commun. 2016 Oct 28;479(4):893-900. doi: 10.1016/j.bbrc.2016.09.087. Epub 2016 Sep 28.
5
Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.针对骨膜蛋白研发工程化肽拮抗剂以克服乳腺癌多柔比星耐药性。
BMC Cancer. 2021 Jan 14;21(1):65. doi: 10.1186/s12885-020-07761-w.
6
Targeted multidrug delivery system to overcome chemoresistance in breast cancer.用于克服乳腺癌化疗耐药性的靶向多药递送系统。
Int J Nanomedicine. 2017 Jan 21;12:671-681. doi: 10.2147/IJN.S124770. eCollection 2017.
7
MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.微小 RNA-574 通过下调乳腺癌细胞中的 SMAD4 增强多柔比星耐药性。
Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1342-1350. doi: 10.26355/eurrev_201803_14476.
8
Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.具有高载药量以逆转乳腺癌多药耐药性的双响应性甲氧基聚乙二醇-聚乳酸-羟基乙酸共聚物-聚谷氨酸杂化核纳米颗粒:体外和体内评价
Acta Biomater. 2015 Apr;16:156-68. doi: 10.1016/j.actbio.2015.01.039. Epub 2015 Feb 4.
9
Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.利用自组装透明质酸纳米载体传递靶向线粒体的阿霉素衍生物治疗多柔比星耐药乳腺癌。
Acta Pharmacol Sin. 2018 Oct;39(10):1681-1692. doi: 10.1038/aps.2018.9. Epub 2018 May 31.
10
Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.使用介孔二氧化硅纳米颗粒药物递送系统提高多药耐药性乳腺癌MCF-7细胞中阿霉素的细胞毒性。
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1337-47. eCollection 2014.

引用本文的文献

1
Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia.用于预测急性髓系白血病生存结局的溶酶体衍生生物标志物。
Discov Oncol. 2025 Aug 2;16(1):1455. doi: 10.1007/s12672-025-03302-8.
2
Targeting Resistance Pathways in Breast Cancer Through Precision Oncology: Nanotechnology and Immune Modulation Approaches.通过精准肿瘤学靶向乳腺癌的耐药途径:纳米技术与免疫调节方法
Biomedicines. 2025 Jul 10;13(7):1691. doi: 10.3390/biomedicines13071691.

本文引用的文献

1
Clinical Significance of Cancer Stem Cell Markers in Primary and Metastatic Tissues in Patients With Breast Cancer.乳腺癌原发和转移组织中肿瘤干细胞标志物的临床意义。
Anticancer Res. 2023 May;43(5):2145-2154. doi: 10.21873/anticanres.16376.
2
Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors.奈必洛尔增敏 BT-474 乳腺癌细胞对成纤维细胞生长因子受体抑制剂的敏感性。
Anticancer Res. 2023 May;43(5):1973-1980. doi: 10.21873/anticanres.16357.
3
A meta-analysis and experimental data for multidrug resistance genes in breast cancer.
乳腺癌多药耐药基因的荟萃分析及实验数据。
Afr Health Sci. 2022 Dec;22(4):1-9. doi: 10.4314/ahs.v22i4.2.
4
Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy.细胞和亚细胞器靶向纳米颗粒介导的乳腺癌治疗
Front Pharmacol. 2023 Apr 6;14:1180794. doi: 10.3389/fphar.2023.1180794. eCollection 2023.
5
Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.靶向 DCLK1 通过抑制 IL-6/STAT3 信号通路衰减三阴性乳腺癌肿瘤干细胞特性并诱导抗肿瘤免疫。
Breast Cancer Res. 2023 Apr 17;25(1):43. doi: 10.1186/s13058-023-01642-3.
6
Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.西达本胺通过促进乳腺癌细胞自噬和凋亡增强阿霉素的细胞毒性。
BMC Cancer. 2023 Apr 17;23(1):353. doi: 10.1186/s12885-023-10774-w.
7
Sufentanil combined with parecoxib sodium inhibits proliferation and metastasis of HER2-positive breast cancer cells and regulates epithelial-mesenchymal transition.舒芬太尼联合帕瑞昔布钠抑制HER2阳性乳腺癌细胞的增殖和转移并调节上皮-间质转化。
Clin Exp Metastasis. 2023 Apr;40(2):149-160. doi: 10.1007/s10585-023-10199-6. Epub 2023 Feb 18.
8
Flotillin-1 promotes EMT of gastric cancer stabilizing Snail. flotillin-1 促进胃癌 EMT 稳定 Snail。
PeerJ. 2022 Aug 15;10:e13901. doi: 10.7717/peerj.13901. eCollection 2022.
9
NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis.通过靶向XIST、hsa-miR-612和MTRNR2L8:综合RNA靶标组相互作用及实验表达分析,NEAT1可作为乳腺癌和胃癌患者的诊断生物标志物。
Genes Environ. 2022 May 17;44(1):16. doi: 10.1186/s41021-022-00244-3.
10
Identification of a Pyroptosis-Related Gene Signature and Effect of Silencing the and in Pancreatic Adenocarcinoma.胰腺癌中焦亡相关基因特征的鉴定及[具体基因]沉默的影响
Int J Gen Med. 2022 Mar 19;15:3199-3213. doi: 10.2147/IJGM.S353849. eCollection 2022.